Sharekhan's research repor on Solara Active Pharma Sciences
It is well poised to grow as a leading ‘global pure-play API company’ given the strong customer relationships, expanding capacities and compliant business operations. Solara’s emphasis on growing the CRAMS business bodes well, and would support the double-digit growth trajectory over the medium term. Solara’s strong growth prospects, better earnings visibility, healthy balance sheet, and improving return ratios would support multiple expansion.
Outlook
We retain our Buy recommendation on Solara Active Pharma Sciences (Solara) with a revised PT of Rs. 1,450. Solara is witnessing strong demand traction across its business segments.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
